03347 泰格醫藥
按盘价 
25.350 -1.400 (-5.234%) | 2024/12 - 末期 人民币(千¥) | 2023/12 人民币(千¥) | 2022/12 人民币(千¥) | 2021/12 人民币(千¥) | 2020/12 人民币(千¥) | |
| 经营活动之现金流量 | 1,097,002 | 1,150,438 | 1,133,551 | 1,162,719 | 892,374 |
| 投资活动之现金流量 | (4,739,122) | (1,534,225) | (2,565,410) | (2,521,608) | (2,231,312) |
| 融资活动之现金流量 | (1,702,410) | (7,806) | 809,249 | (163,093) | 9,339,458 |
| 现金及等同现金之增加/(减少) | (5,344,531) | (391,593) | (622,610) | (1,521,982) | 8,000,520 |
| 期初之现金及现金等价物 | 7,399,941 | 7,782,741 | 8,378,417 | 9,959,963 | 2,006,926 |
| 汇率变动之影响 | (6,917) | 8,793 | 26,934 | (59,564) | (47,483) |
| 其他 | 0 | 0 | 0 | 0 | 0 |
| 期末之现金及现金等价物 | 2,048,494 | 7,399,941 | 7,782,741 | 8,378,417 | 9,959,963 |
| 备注： | 实时报价更新时间为16/05/2025 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB 405,143 |
| 增长率 | -79.991% |
| 每股盈利/(亏损) | RMB 0.470 |
| 每股账面资产净值 (¥) | RMB 24.000 |